Psoriatic Arthritis 
The MD Magazine Psoriatic Arthritis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.


Pfizer Seeks to Expand Tofacitinib Approval to Include Psoriatic Arthritis
FDA to consider Xeljanz, the sole JAK inhibitor available in US, for new indication.
Infliximab-abda approved for range of gastroenterological and rheumatoid conditions.
Pso and PsA are associated with higher rates of pathological fractures.
Allan Gibofsky, MD, highlights the goals of treatment for patients with psoriatic arthritis and discusses how routine imaging procedures are used to monitor for treatment efficacy and disease progression.
Allan Gibofsky, MD, reveals common rheumatologic measurement tools used in considerations for optimizing treatment for patients with psoriatic arthritis.
Despite their effectiveness in treating psoriatic arthritis, biologic agents may carry a risk for infection. As a result, Allan Gibofsky, MD, discusses how rheumatologists manage patients being treated with a biologic agent.
Allan Gibofsky, MD, briefly discusses the normal protocol for monitoring and treating patients with psoriatic arthritis and remarks on the potential benefits of using biologic therapy in patients with this condition.
Allan Gibofsky, MD, highlights the various ways that psoriatic arthritis may present in patients and, consequently, remarks on the importance of seeking a rheumatologist to help distinguish an appropriate diagnosis.
Allan Gibofsky, MD, a professor of medicine at Weill Cornell Medicine and an attending rheumatologist at Hospital for Special Surgery in New York, provides an overview of the rheumatic diseases psoriatic arthritis and ankylosing spondylitis.

Most Popular


$vacMongoViewPlus$ $vAR$